Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Highlights from ESMO: DESTINY-Breast03

Elena Garralda • 29 Sep 2021
ESMO 2021
Breast Cancer General Antibodies Trastuzumab deruxtecan Trastuzumab emtansine
DESTINY-Breast03

Elena Garralda, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, comments on the importance of the results of the DESTINY-Breast03 trial (NCT03529110) demonstrating the efficacy of trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Elena Garralda

2:54
Safety and efficacy of SKB264 for the treatment of advanced or metastatic solid tumors
Elena Garralda • 29 Sep 2021
2:31
DS-7300 for the treatment of advanced solid tumors
Elena Garralda • 29 Sep 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals